Boston Scientific Corp. made its $25 billion bid for heart devices maker Guidant Corp. official on Sunday, but rival bidder Johnson & Johnson reiterated that it's committed to buying Guidant itself. Boston Scientific is willing to pay 12 percent more than J&J, which originally offered $25.4 billion in cash last year, but cut that to $21 billion in November after problems surfaced with Indianapolis-based Guidant's cardiac devices.
January 10, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Boston Scientific Corp. made its $25 billion bid for heart devices maker Guidant Corp. official on Sunday, but rival bidder Johnson & Johnson reiterated that it is committed to buying Guidant itself.
Natick, Mass.-based Boston Scientific, which last month indicated it would launch a competing bid for the approved $21 billion deal with J&J, said it would pay $72 a share for Boston Scientific, divided evenly between cash and stock.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
